Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer

September 25, 2017
Douglas A. Levine, MD

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the efficacy of niraparib (Zejula) on progression-free survival in patients with recurrent ovarian cancer with partial response to the last platinum-based chemotherapy.